ICON Releases its 2021 ESG Report
The report outlines how ICON is delivering on its ESG commitments and measured its performance in a number of key areas, including the social impact it is having on advancing public health, its continued diversity and inclusion focus, how it conducts its business sustainably and its commitment to ethics and quality.
On the publication of the report,
Examples of how ICON progressed its ESG commitments in 2021 include:
Advancing public health
ICON’s work spans continents, delivering services in developed countries and traditionally underserved regions and helps to improve access to healthcare for people worldwide.
ICON did significant work in 2021 in the fight against COVID-19. This included providing clinical trials services to the
In 2021, the company invested in patient centric innovation using technology and partnerships. In addition to developing strategic partnerships across the healthcare ecosystem to drive increased access to healthcare, ICON has focused on innovative approaches and technologies to drive progress in clinical research.
Focus on diversity and inclusion
In 2021, ICON focused on promoting diversity within its own company and the industry overall. From a patient perspective, one of ICON’s key ambitions is to make it easier for patients, across all dimensions of diversity, to be part of clinical research. In its work with
Within its own company, community groups are one of the ways in which ICON promotes diversity, inclusion and belonging, by bringing together employees with common identities and related interests. These groups are:
-
NOW@ICON:
The Networking Organisation for Women at ICON - PRIDE: Supporting LGBTQ+ colleagues and allies
- DAWN: The Disability Awareness Network
- SPACE: Supporting Parents and Carers Everywhere
- EmbRACE: Supporting all race and ethnic backgrounds
Conducting business sustainably
ICON is actively managing its environmental impact across its global business. Progress achieved in 2021 included:
-
40% of the way to reducing electricity consumption by20% by 2030. -
Since 2018, Scope 3 business travel emissions have decreased by
60% . - Consolidated 37 office locations to align with new working styles and business needs. This includes office building closures and modifications and a flexible working policy.
Supporting communities
In addition to the pivotal role ICON played in COVID-19 vaccine development, the company also participated in the
ICON also continued with its employee-led charitable donation program, which has supported over 90 charities since 2012. During 2021, ICON donated
For further information about ICON’s ESG efforts in 2021, please visit:www.iconplc.com/about/esg/
About
ICON is the world’s leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005335/en/
Corporate Communications,
+353 87 4066091
claire.quinn@iconplc.com
Vice President Investor Relations,
+1-888-381-7923
IR@iconplc.com
Source: